Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester

Hamazaki, Tomohito; Takazakura, Eisuke; Osawa, Kenzo; Urakaze, Masaharu; Yano, Saburo

doi:10.1007/bf02537161

Cited by 52 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequent evaluation of the abstract and methods sections led to exclusion of 46 studies. Reasons for exclusion included the following: publications that did not assess fish oil supplementation (15 articles [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]), nonrandomized studies (11 articles [34][35][36][37][38][39][40][41][42][43][44]), the population had patients without diabetes or patients with type 1 diabetes (8 articles [45][46][47][48][49][50][51][52]), duplicate publications (7 articles [53][54][55][56][57][58][59]), studies that did not include a placebo arm (3 articles [60][61][62]), and 1 study that did not include human subjects (63). The 12-month follow-up report of the Italian Multicenter Fish Oil Study (64) was excluded because it is a nonrandomiz...…”

Section: Search Resultsmentioning

confidence: 99%

Fish oil supplementation in type 2 diabetes: a quantitative systematic review.

et al. 2000

View full text Add to dashboard Cite

Abbreviations: DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HMG-CoA, 3-hydroxy 3-methylglutaryl CoA.A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many other substances. Fish Oil Supplementation in Type 2 DiabetesA quantitative systematic review R E V I E W A R T I C L EOBJECTIVE -To determine the effects of fish oil supplementation on lipid levels and glycemic control in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS-A comprehensive search of Medline, Embase, Lilacs, the Cochrane Clinical Trials Registry, bibliographies of relevant papers, and expert input updated through September 1998 was undertaken. All randomized placebo-controlled trials were included in which fish oil supplementation was the only intervention in subjects with type 2 diabetes. Three investigators performed data extraction and quality scoring independently with discrepancies resolved by consensus. Eighteen trials including 823 subjects followed for a mean of 12 weeks were included. Doses of fish oil used ranged from 3 to 18 g/day.The outcomes studied were glycemic control and lipid levels.RESULTS -Meta-analysis of pooled data demonstrated a statistically significant effect of fish oil on lowering triglycerides (Ϫ0.56 mmol/l [95% CI Ϫ0.71 to Ϫ0.41]) and raising LDL cholesterol (0.21 mmol/l [0.02 to 0.41]). No statistically significant effect was observed for fasting glucose, HbA 1c , total cholesterol, or HDL cholesterol. The triglyceride-lowering effect and the elevation in LDL cholesterol were most marked in those trials that recruited hypertriglyceridemic subjects and used higher doses of fish oil. Heterogeneity was observed and explained by the recruitment of subjects with baseline hypertriglyceridemia in some studies. CONCLUSIONS R e v i e w s / C o m m e n t a r i e s / P o s i t i o n S t a t e m e n t s 1408DIABETES CARE, VOLUME 23, NUMBER 9, SEPTEMBER 2000 Fish oil in type 2 diabetesOutcome measures and data extraction Study selection, data extraction, and assigning of a quality score were undertaken independently by 3 investigators with discrepancies resolved by consensus. When data were not available in a published report, efforts were made to contact the primary investigators. Data related to the effects of fish oil and placebo on glycemic and lipid outcomes were extracted from each trial. One study reported total glycosylated hemoglobin; a formula was used to convert data to HbA 1c (15). Study quality was assessed using the score developed by Jadad et al. (16), which has a possible range of 0-5, with a cutoff of 2 used to designate studies of high versus low quality. Data analysis and statistical methodsExtracted data were analyzed using the Review Manager 3.1 statistical software developed by the Cochrane Collaboration.A random-effects model was used to pool data. Effect sizes are presented as weighted mean differences with 95% CIs. Heterogeneity was assessed using the 2 method. Publication bias was evaluated using a funnel plot method (1...

show abstract

Section: Search Resultsmentioning

confidence: 99%

Fish oil supplementation in type 2 diabetes: a quantitative systematic review.

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Hamazaki et al [37] described a decrease in MA in DM type 2 after administration of EPA ethylester in a daily dose of 1.8 g for 6 months. These changes were associated with a significant increase in EPA in plasma.…”

Section: Discussionmentioning

confidence: 98%

N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin–fibrate combination

Zeman

Žák

Vecka

et al. 2006

The Journal of Nutritional Biochemistry

View full text Add to dashboard Cite

“…Two studies which investigated the effect of long-chain omega-3 PUFAs supplementation on albuminuria in patients with type 1 diabetes failed to show a significant reduction in albuminuria [78,79]. In contrast, EPA supplementation resulted in a significant reduction in albuminuria in Japanese patients with type 1 and type 2 diabetes [80,81]. Racial disparities may be involved in these discrepancies, as it has been suggested that the response to long-chain omega-3 fatty acid or fish consumption may differ between Western and Asian populations [82].…”

Section: Pufasmentioning

confidence: 99%

Dyslipidemia in diabetic nephropathy

2016

View full text Add to dashboard Cite

Diabetic nephropathy (DN) not only is a major cause of end-stage renal disease (ESRD) in developing and developed countries but also plays a critical role as a risk factor for cardiovascular disease. The pathogenesis of DN is multifactorial and remains to be elucidated. It is well known that dyslipidemia is frequently complicated with diabetes. Recently, dyslipidemia has been recognized to be involved in the progression of DN. In general, diabetic dyslipidemia is caused by impaired action of lipoprotein lipase (LPL) that is localized to the endothelial cells, resulting in increased serum levels of increased triglyceride (TG) and decreased high-density lipoprotein cholesterol (HDL-C). Smaller size and modified low-density lipoprotein (LDL), such as glycated and oxidized LDL, play important roles to induce vascular and renal cellular dysfunction. Previous studies demonstrated that dyslipidemia enhances macrophage infiltration and excessive extracellular matrix (ECM) production in the glomeruli under diabetic conditions, leading to the development of DN. Clinical studies have demonstrated that lipid-lowering therapy shows a protective effect on the renal function. It is well known that statins reduce albuminuria in patients with DN. A series of our studies indicated that this effect is mediated by Rho-kinase inhibition. Rho-kinase plays a key role in the pathogenesis of DN by activating the inflammatory pathway, including oxidative stress, NF-κB, and hypoxia inducible factor (HIF)-1. Intriguingly, Rho-kinase inhibitors have been shown to attenuate glomerulosclerosis as well as atherosclerosis. Therefore, Rho-kinase could be a promising therapeutic target for both DN and cardiovascular disease.

show abstract

Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester

Cited by 52 publications

References 29 publications

Fish oil supplementation in type 2 diabetes: a quantitative systematic review.

Fish oil supplementation in type 2 diabetes: a quantitative systematic review.

N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin–fibrate combination

Dyslipidemia in diabetic nephropathy

Contact Info

Product

Resources

About